Paper Details

  1. Home
  2. Paper Details

MicroRNA-Mediated Drug Repurposing Unveiled Potential Candidate Drugs for Prolactinoma Treatment.

Author: ArgaKazim Yalcin, ArslanSema, AydinBusra, BayraklıFatih, KarademirBetul

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Prolactinomas are the most common hormone-secreting pituitary tumors. Dopamine agonists (DAs), particularly cabergoline, are the preferred first-line treatment for reducing prolactin levels, tumor volume, and mass effect. However, some patients experience DA resistance, aggressive tumor behavior, or recurrence after drug withdrawal. Current treatments have significant side effects and negatively impact quality of life.
Paper Details　
Original Abstract of the Article :
Prolactinomas, also called lactotroph adenomas, are the most encountered type of hormone-secreting pituitary neuroendocrine tumors in the clinic. The preferred first-line therapy is a medical treatment with dopamine agonists (DAs), mainly cabergoline, to reduce serum prolactin levels, tumor volume, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000515801

データ提供：米国国立医学図書館（NLM）

Unveiling New Hope for Prolactinoma Treatment: A MicroRNA-Mediated Approach

Prolactinomas, a type of pituitary tumor, are like a rogue camel in the desert, disrupting the delicate balance of hormones. While dopamine agonists (DAs) are commonly used to rein in these tumors, some patients find them ineffective or experience undesirable side effects. This research delves into the world of microRNAs, tiny but powerful molecules that regulate gene expression. The authors suggest that by understanding how microRNAs interact with these tumors, we can potentially repurpose existing drugs to create more effective treatments. This approach could offer a new oasis in the desert of prolactinoma treatment, providing more targeted and less invasive options.

A New Path in the Desert

The study suggests that microRNA-mediated drug repurposing could unlock a new arsenal of effective treatments for prolactinomas. This could mean a future where patients experience fewer side effects and enjoy better outcomes.

A Brighter Future for Prolactinoma Patients

This research offers hope for those living with prolactinomas, highlighting a potentially more effective and less invasive treatment approach. As we explore the intricate world of microRNAs, new pathways to better health are likely to emerge.

Dr. Camel's Conclusion

This research is a testament to the power of microRNAs, highlighting their potential to revolutionize the treatment of prolactinomas. By understanding how these tiny molecules orchestrate cellular processes, we can potentially unlock new and more effective therapies for those navigating the challenges of these tumors.

Date :
  1. Date Completed 2022-03-03
  2. Date Revised 2022-03-03
Further Info :

Pubmed ID

33706313

DOI: Digital Object Identifier

10.1159/000515801

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.